NCT02141035View on ClinicalTrials.gov

Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

September 30, 2017

Conditions
Carpal Tunnel SyndromeCompression Neuropathy
Interventions
DRUG

Acetyl-l-carnitine

Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days

DRUG

placebo

The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days

Trial Locations (3)

T5G 0B7

Glenrose Hosptial, Edmonton

T5H 3V9

Royal Alexandra Hospital, Edmonton

T5R2E1

University of Alberta Hospital, Edmonton

All Listed Sponsors
lead

University of Alberta

OTHER

NCT02141035 - Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome | Biotech Hunter | Biotech Hunter